Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451006 · ClinicalTrials.gov registry record · Phase 2
Effect of Metformin on Frailty in 12 Subjects
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03451006: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT03451006 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03451006, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study will test whether chronic metformin administration will improve longevity of the cell, improves its machinery by reducing aging-related biochemical parameters and thereby improving physical performance, as measured by short physical performance battery test.
Interventions
- DRUG Placebo
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-05-24 |
| Est. Completion | 2021-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03451006
The ClinicalTrials.gov registry entry for NCT03451006 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03451006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03451006 about?
NCT03451006 is a clinical study titled "Effect of Metformin on Frailty in 12 Subjects". This study will test whether chronic metformin administration will improve longevity of the cell, improves its machinery by reducing aging-related biochemical parameters and thereby improving physical performance, as measured by short physical performance battery test.
What is the current status of trial NCT03451006?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2018-05-24. Estimated completion is 2021-12-16.
What interventions are being tested in trial NCT03451006?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG).
Who is sponsoring clinical trial NCT03451006?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.